AQR Capital Management
ZBIO

AQR Capital Management’s Zenas BioPharma ZBIO Stock Holding History

AQR Capital Management’s Portfolio ZBIO Stock Details ZBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$996K Sell
50,971
-27,249
-35% -$612K ﹤0.01% 2776
2025
Q4 		$2.84M Buy
78,220
+53,636
+218% +$1.76M ﹤0.01% 1916
2025
Q3 		$546K Sell
24,584
-84
-0.3% -$1.37K ﹤0.01% 2775
2025
Q2 		$239K Buy
+24,668
New +$240K ﹤0.01% 2969

Other funds holding ZBIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NA
NVP Associates Menlo Park, California $176M AUM 208.78% 1-Year Est. Return

AQR Capital Management's ZBIO Position: Q1 2026 in Review

AQR Capital Management reduced its Zenas BioPharma (ZBIO) stake by 35% in Q1 2026, selling an estimated $612K and leaving 50,971 shares worth $996K. The position accounts for ﹤0.01% of the portfolio, ranked #2776.

AQR Capital Management first reported a position in ZBIO in Q2 2025 and has held it in 4 quarters since. The position peaked at $2.84M in Q4 2025. 139 funds tracked by Wall St. Rank hold ZBIO as of Q1 2026.

  • AQR Capital Management held 50,971 shares of Zenas BioPharma worth $996K as of Q1 2026.
  • AQR Capital Management sold 27,249 Zenas BioPharma shares in Q1 2026, an estimated $612K.
  • Zenas BioPharma made up ﹤0.01% of AQR Capital Management's portfolio in Q1 2026, its #2776 holding.
  • AQR Capital Management first reported a position in Zenas BioPharma in Q2 2025 and has held it in 4 quarters since.
  • AQR Capital Management's Zenas BioPharma position peaked at $2.84M in Q4 2025.
  • 139 funds tracked by Wall St. Rank held Zenas BioPharma as of Q1 2026.

Based on AQR Capital Management's 13F filing for Q1 2026, filed 15 May 2026.